Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 39 (4), 452-5

Pharmacokinetics of Ifosfamide and Its Enantiomers Following a Single 1 H Intravenous Infusion of the Racemate in Patients With Small Cell Lung Carcinoma

Affiliations
Clinical Trial

Pharmacokinetics of Ifosfamide and Its Enantiomers Following a Single 1 H Intravenous Infusion of the Racemate in Patients With Small Cell Lung Carcinoma

S A Corlett et al. Br J Clin Pharmacol.

Abstract

Ifosfamide is a chiral pro-drug which is administered clinically in its racemic form. Serum concentrations of rac-ifosfamide and its enantiomers were measured in 12 patients with lung carcinoma following a mean (+/- s.d.) intravenous dose of 4.2 (0.83) g infused over 1 h. The mean (+/- s.d.) volumes of distribution (VSS) of rac, (R)- and (S)-ifosfamide were 0.61 (0.17), 0.60 (0.16) and 0.61 (0.19) l kg-1, respectively. The mean (+/- s.d.) half-lives and clearances were 6.57 (1.69), 7.12 (1.92) and 5.98 (1.52) h and 0.065 (0.013), 0.060 (0.013) and 0.072 (0.014) l h-1 kg-1 for rac, (R)- and (S)-ifosfamide, respectively. The half-life of (S)-ifosfamide was significantly (P < 0.001) shorter than that of (R)-ifosfamide and it had a significantly higher clearance (P < 0.001). There was no significant difference in the volumes of distribution of the enantiomers. The clinical significance of the faster elimination of (S)-ifosfamide is not known.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. Cancer Chemother Pharmacol. 1989;25(2):139-42 - PubMed
    1. Cancer Res. 1989 Feb 1;49(3):753-7 - PubMed
    1. Br J Clin Pharmacol. 1990 Jul;30(1):140-3 - PubMed
    1. Br J Clin Pharmacol. 1990 Nov;30(5):725-32 - PubMed
    1. Br J Clin Pharmacol. 1991 Jan;31(1):77-82 - PubMed

Publication types

Feedback